The molecular subtypes of the 38 AI-detected breast cancer patients with available immunohistochemical profiles were luminal A in 55.3% (21/38), luminal B in 23.7% (9/38), HER-2 positive in 10.5% (4/38), and triple-negative in 10.5% (4/38). Here, ERBB2 is linked to breast cancer.